Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave, Innogenetics Settle Patent Suit

NEW YORK, Feb. 9 (GenomeWeb News) - Third Wave and Innogenetics have settled a patent-infringement suite Innogenetics filed against Third Wave last September, the companies said today.


Under the agreement, Third Wave will get a non-exclusive license to sell Innogenetics hepatitis C genotyping products and the option to extend the license to the entire HCV patent estate.


"We are particularly happy to have concluded this licensing agreement. The amicable resolution of this issue will help both companies realize their ambitious near- and mid-term goals," said Innogenetics CEO Frank Morich.


Financial details were not disclosed.


As GenomeWeb News reported, Innogenetics sued Third Wave Technologies and Abbott Laboratories for allegedly infringing its HCV genotyping patents. The disposition of the Abbott suit was not immediately clear.


In the suits, filed with the US District Court for the Western District of Wisconsin, Gent, Belgium-based Innogenetics claimed that both Abbott and Third Wave have been infringing its US Patent No. 5,846,704, which covers a process for typing HCV isolates. Both companies have refused to take a license to the technology, according to Innogenetics. The company said it expects a ruling within 12 months.


Third Wave and Innogenetics have been partners since at least April 2004, when the two companies signed a four-year marketing and distribution agreement, under which Innogenetics distributes a number of Third Wave's Invader molecular diagnostic products exclusively in Europe.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.